Swiss Life Asset Management Ltd Purchases 6,082 Shares of Amgen Inc. $AMGN

Swiss Life Asset Management Ltd grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.3% during the third quarter, HoldingsChannel.com reports. The firm owned 271,340 shares of the medical research company’s stock after purchasing an additional 6,082 shares during the period. Swiss Life Asset Management Ltd’s holdings in Amgen were worth $76,572,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Evelyn Partners Investment Management LLP bought a new position in Amgen in the 2nd quarter valued at approximately $32,000. Howard Hughes Medical Institute bought a new stake in Amgen during the 2nd quarter worth approximately $32,000. Cloud Capital Management LLC bought a new stake in Amgen during the 3rd quarter worth approximately $34,000. AXS Investments LLC acquired a new position in Amgen in the 3rd quarter valued at approximately $42,000. Finally, Winnow Wealth LLC acquired a new position in Amgen in the 3rd quarter valued at approximately $47,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Down 2.7%

NASDAQ:AMGN opened at $351.48 on Thursday. The firm’s fifty day moving average is $359.46 and its 200-day moving average is $326.94. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The firm has a market cap of $189.47 billion, a P/E ratio of 24.70, a P/E/G ratio of 3.58 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the firm earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analysts lifted Amgen’s fair value amid optimism around obesity candidate MariTide and execution, which supports a stronger medium-term outlook for earnings. How The Amgen (AMGN) Narrative Is Shifting With MariTide Hopes And Exclusivity Concerns
• Positive Sentiment: Billionaire Ken Fisher increased his Amgen stake, a signal of institutional confidence that can support investor sentiment. Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position
• Neutral Sentiment: Short-interest print shows zero shares (and NaN change), which appears to be a reporting error; it doesn’t offer actionable insight into current positioning.
• Neutral Sentiment: Sector/biotech financing note — Crossbow raised $77M for an oncology T‑cell engager program; industry capital flow can influence sentiment but it doesn’t directly affect Amgen’s fundamentals. Crossbow raises $77M for new cancer immunotherapies
• Negative Sentiment: Report says Amgen will join TrumpRx and offer an ~80% discount on Amjevita — a move that could pressure revenue/margins for that product and raise investor concern about pricing concessions. Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
• Negative Sentiment: Market headlines reporting that AMGN closed lower amid a broader market uptick — confirms the stock is underperforming today and may be reacting to the items above. Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Wall Street Analyst Weigh In

Several research firms have recently issued reports on AMGN. Oppenheimer set a $400.00 price target on shares of Amgen and gave the company an “outperform” rating in a research note on Thursday, January 29th. Daiwa Securities Group increased their price objective on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. TD Cowen reaffirmed a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. Citigroup lifted their target price on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Finally, Sanford C. Bernstein lowered Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $354.00.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.